Kwangdong Empaglo Tablets 10 mg (Empagliflozin)
Empagliflozin 10mg
Tablet · Prescription medication
Kwangdong Pharmaceutical Co., Ltd.
MFDS item code 202105608 · Approved 2021.07.29
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used in conjunction with dietary and exercise therapy to improve blood sugar control in adults with type 2 diabetes. It can be administered as monotherapy or in combination with other medications. It is especially used in patients with difficulty in controlling blood sugar and existing cardiovascular disease, in which case it should be managed carefully under a specialist's guidance. This medication helps effectively control blood sugar levels, thereby improving patients' health.
The recommended dose of this medicine for monotherapy and as add-on combination therapy with other glucose-lowering agents, including insulin, is 10 mg once daily. If 10 mg of this medicine is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, section 3. Adverse Reactions). This medicine may be taken regardless of food. Swallow the tablet whole. If a dose is missed, take it as soon as remembered. Do not take a double dose in one day. Special populations •Patients with renal impairment No dose adjustment is necessary for patients with mild renal impairment. Do not initiate treatment with this medicine in patients with an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent estimated glomerular filtration rate below 60ml/min/1.73m2 [or CrCl < 60 ml/min], adjust or maintain the dose of this medicine at 10 mg once daily. Discontinue this medicine if the estimated glomerular filtration rate decreases to below 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those undergoing dialysis, as efficacy is not expected. •Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as they have not been studied. •Older adults No dose adjustment based on age is necessary. Renal function and the risk of volume depletion should be considered in patients aged 75 years and older. Initiation of this medicine is not recommended in patients aged 85 years and older because clinical experience is limited (see Precautions for Use, section 4. General Precautions)
This medication should not be used in patients who have allergies to the active or inactive ingredients. It should not be administered to patients with type 1 diabetes or diabetic ketoacidosis. This medication is not to be used in patients with severely impaired renal function, that is, those with a glomerular filtration rate of less than 30 mL/min/1.73m2, end-stage kidney disease patients, or those undergoing dialysis. This medication contains lactose and should not be administered to patients with lactose intolerance, galactose intolerance, hereditary lactase deficiency, or glucose-galactose malabsorption. Caution is advised when administering to patients with slightly impaired renal function, and the dosage should be adjusted or discontinued if renal function continues to decline. In patients with heart failure classified as NYHA class I-II, caution is advised, while use is not recommended in patients classified as class III-IV. Coadministration with insulin or sulfonylureas may increase the risk of hypoglycemia, thus adjustment of their dosages may be necessary. During treatment with this medication, adverse reactions such as hypoglycemia, genital infections, urinary tract infections, increased urination, and decreased fluid volume may occur. There is a particular risk of serious conditions such as ketoacidosis, thus immediate consultation with a healthcare professional is advised upon symptom occurrence. Elderly patients or those at risk of fluid volume loss should be cautious due to the potential for low blood pressure or dehydration. This medication increases the risk of genital fungal infections, so appropriate treatment is necessary if related symptoms arise. Regular monitoring of kidney function and fluid status during treatment is important. Use during pregnancy should be avoided, and breastfeeding should be discontinued if necessary. Safety and effectiveness in children under 18 years of age have not been established. No specific toxic symptoms have been reported in case of overdose, but appropriate treatment is necessary depending on the clinical condition. This medication should be kept out of the reach of children and should not be transferred to other containers. Particular caution should be taken when driving or operating machinery, especially when taken with insulin or sulfonylureas due to the increased risk of hypoglycemia. Serious side effects, such as limb amputation or perineal necrosis, have been rarely reported; hence, immediate consultation with a healthcare professional should be sought if related symptoms appear.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture. Additionally, it is recommended to keep the medication at room temperature between 1°C and 30°C, avoiding extremes of heat or cold.
Pale yellow round film-coated tablet
30 tablets/PTP (10 tablets/PTP × 3), 10 tablets/PTP (10 tablets/PTP × 1)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin 10mg
Tablet · Prescription medication
Kwangdong Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.